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Abstract
Background: Klotho, a protein linked to aging, has emerged as a pivotal player in mineral bone metabolism and might
explain the relationship between chronic kidney disease (CKD) and cardiovascular disease (CVD). The present study aimed
to investigate the association between serum klotho and cardiac parameters from a large-scale Korean CKD cohort.
Methods: We analyzed 2101 participants from KoreaN Cohort Study for Outcome in Patients With Chronic Kidney
Disease (KNOW-CKD) cohort who had been measured for serum klotho levels. Left ventricular hypertrophy evaluated by
left ventricular mass index (LVMI) and arterial stiffness measured by brachial-to-ankle pulse wave velocity (baPWV) were
explored as cardiovascular parameters.
Results: Patients were 53.6 ± 12.2 years old and 61.1% were male. The mean estimated glomerular filtration rate (eGFR)
was 53.0 ± 30.7 mL/min/1.73m2. The median serum klotho level was 536 (interquartile range [IQR]: 420–667) pg/mL.
Advanced CKD stages were associated with lower serum klotho levels (P < 0.001, P for linear trend < 0.001). Ascending
quartiles of klotho were significantly associated with decreased LMVI (P < 0.001, P for linear trend< 0.001). A multivariable
linear regression model showed serum klotho had a significant inverse association with LVMI (β − 0.04; 95% CI
[confidence interval] -0.004, − 0.00007; P = 0.041). However, there was no significant association between serum klotho
and baPWV after adjustment (β 0.003; 95% CI -0.04, 0.05; P = 0.876).
Trial registration: This trial was registered on ClinicalTrials.gov on 28 June 2012 (NCT01630486).
Conclusions: Serum klotho was an independent biomarker of LVMI, but not arterial stiffness.
Keywords: Serum klotho, Soluble klotho, Chronic kidney disease, Left ventricular mass index, Left ventricular hypertrophy,
Pulse wave velocity
Background
Patients with chronic kidney disease (CKD) present with a
higher burden of cardiovascular disease (CVD) and cardio-
vascular mortality than the general population [1, 2]. Left
ventricular myocardial hypertrophy, the most commonly
diagnosed cardiovascular abnormality in CKD patients, is
secondary to both volume and pressure overload [3]. Car-
diac hypertrophy is an important cause of cardiovascular
morbidity and mortality for CKD patients because it can
lead to congestive heart failure, arrhythmia, ischemic
cardiomyopathy, even in the absence of coronary artery
disease, and sudden death in CKD patients [4–6]. Arterial
stiffness in CKD patients caused by arteriosclerosis with
thickening and stiffening of the arterial wall [7] brings
about cardiac hypertrophy and a negative prognostic value
for CVD [8, 9].
Mineral bone metabolism is important in CKD, and
progressive deterioration of calcium-phosphorus homeo-
stasis is associated with cardiovascular complications.
Impaired calcium-phosphorus homeostasis can cause
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cardiac hypertrophy and vascular calcification. Klotho
has emerged as a pivotal player in calcium-phosphorus
homeostasis and mineral metabolism regulation in CKD,
and it might explain the relationship between CKD and
CVD. The Klotho gene, which was originally identified
as an aging suppressor gene, is closely associated with
CKD. In a previous study, klotho knock-out mice had
similarities with CKD patients, such as hyperphosphate-
mia, ectopic soft tissue calcification, and arteriosclerosis
[10], suggesting that CKD might result from a state of
klotho deficiency. Thus, in addition to serving as a bio-
marker for CKD, klotho deficiency is also a pathogenetic
indicator for both renal and extra-renal complications in
CKD [11]. In previous experimental studies, restoration
of serum klotho levels ameliorated cardiac hypertrophy
and vascular calcification [12, 13], and haplodeficiency
of the Klotho gene caused arterial stiffness [14]. Clinical
data supporting the above experimental studies are
scarce and present mixed results [15]. Yang et al. [16]
showed that cardiac hypertrophy evaluated by left ven-
tricular mass index (LVMI) was negatively associated
with serum klotho in 86 CKD patients. They did not
show the association between klotho and LVMI for CKD
patients in an adjustment model. In another study, there
was no significant association between serum klotho and
LVMI in dialysis patients [17]. Previous studies have
been conducted on a small number of patients and few
studies have focused on CKD patients for the association
between klotho and LVMI. Given the negative effects of
klotho deficiency, its associated cardiovascular complica-
tions in preclinical studies, and the limited number of
clinical studies, the current study aimed to investigate
the association between serum klotho and cardiovascular
parameters in CKD patients, using the baseline cross-
sectional data set of a large-scale Korean CKD cohort.
Methods
Study population
The KoreaN Cohort Study for Outcome in Patients With
Chronic Kidney Disease (KNOW-CKD) was a Korean mul-
ticenter prospective cohort study that enrolled participants
with CKD from stage 1 to 5 (predialysis) from nine clinical
centers of major university-affiliated hospitals in Korea. De-
tails about the study design and methods are described else-
where [18]. Subjects with severe heart failure (New York
Heart Association Class III or IV) were excluded from en-
rollment according to study protocol. Among the 2238 par-
ticipants enrolled in the KNOW-CKD study from June2011
to January2016, 2113 individuals had their serum klotho
levels assayed. Twelve patients were excluded as extreme
values (serum klotho either lower than detectable range or
above 6000 pg/mL). These values were not influence value
by Cook’s distance analysis. Finally 2101individualswere in-
cluded in the cross-sectional analysis. The study protocol
was approved by the ethical committee of each participat-
ing clinical center, including the Institutional Review Boards
of Seoul National University Hospital, Severance Hospital,
Kangbuk Samsung Medical Center, Seoul St. Mary’s
Hospital, Gil Hospital, Eulji General Hospital, Chonnam
National University Hospital, and Busan Paik Hospital. All
participating patients provided written informed consent.
The study protocol was in accordance with the principles
of the Declaration of Helsinki.
Clinical data collection and laboratory analyses
Baseline demographic characteristics and laboratory values
at enrollment were extracted from an electronic data man-
agement system (http://www.phactaX.org). Serum creatin-
ine was measured by an isotope dilution mass spectrometry
(IDMS)-traceable method [19] at a central laboratory. The
estimated glomerular filtration rate (eGFR) was estimated
using the Chronic Kidney Disease Epidemiology Collabor-
ation (CKD-EPI) creatinine eq. [20].The serum α-klotho
level was measured using an enzyme-linked immunosorb-
ent assay (ELISA) kit (Immuno-Biological Laboratories Co.,
Gunma, Japan) according to the manufacturer’s protocol l
[21]. The intra-assay and inter-assay coefficients of vari-
ation were 2.7–3.5% (Klotho levels186.64–2968.78 pg/mL)
and 2.9–11.4% (Klotho levels 165.47–2903.01 pg/mL), re-
spectively. The data for intra-assay and inter-assay coeffi-
cients of variations were confirmed in our central
laboratory by measurements of a serum control in 20 re-
peats on each ELISA plate. The intra-assay and inter-assay
coefficients of variations were 0.57–1.78% and 3.01–6.12%
(Klotho levels 120.30–4468.50 pg/mL), respectively. The
standard curve was found to be linear up to 4000 pg/mL.
C-terminal FGF23 was measured using second generation
human FGF23 ELISA kit (Immutopics, San Clemente,
California, USA) according to the manufacturer’s protocol.
The intra-assay and inter-assay coefficients of variation as
reported by the manufacturer were 1.4–2.4% (FGF23 levels
33.7–302 RU/mL) and 2.4–4.7% (FGF23 levels 33.6–293
RU/mL), respectively.
Cardiovascular parameters
Cardiovascular parameters were evaluated using left ven-
tricular mass index (LVMI) and pulse wave velocity (PWV),
which represent left ventricular hypertrophy and arterial
stiffness, respectively. Two-dimensional echocardiography
was conducted by experts at each hospital, and the LVMI
was calculated by dividing the left ventricular (LV) mass by
theheight2.7 [22]. LVMI was calculated in the cohort center
using the same formula. LV mass was calculated by the for-
mula 0.8 x{1.04×[(LVIDd +PWTd + SWTd)3 - LVIDd3]} +
0.6 (g), where LVIDd, PWTd, and SWTd are LV internal
diameter at end diastole, posterior wall thickness at end
diastole, and septal wall thickness at end diastole, respect-
ively [23]. Left ventricular hypertrophy (LVH) was defined
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as LVMI ≥50 g/m2.7 in men and ≥47 g/m2.7in women [24].
Relative wall thickness (RWT) was calculated to as two
times posterior wall thickness/LV internal linear dimension
in diastole (RWT= [2 x PWTd]/LVIDd). RWT was consid-
ered to be increased if > 0.42. LVMI and RWT were used
to categorize LV geometry: normal (normal LVMI and nor-
mal RWT), concentric remodeling (normal LVMI and
RWT> 0.42), concentric LVH (increased LVMI and RWT>
0.42), eccentric LVH (increased LVMI and RWT ≤ 0.42).
Systolic heart dysfunction and diastolic heart dysfunction
were defined as an LV ejection fraction < 50% and a ratio
(E/E’ ratio) of mitral peak velocity of early filling (E) to early
diastolic mitral annular velocity(E’) > 15 on echocardiog-
raphy, respectively [25, 26].Arterial stiffness was measured
with brachial-to-ankle PWV (baPWV) and heart-to-
femoral PWV (hfPWV) [27]. Among the nine participating
centers, hfPWV was measured only at five centers where
the equipment was available. hfPWV represented central
arterial stiffness, while baPWV represented peripheral ar-
terial stiffness. The abdominal aorta calcification(AAC)
score was measured with simple lateral lumbar radiography
with a range of 0 to 24 [28]. The coronary artery calcium
score (CACS) was measured by computed tomography and
was presented as the Agatson score [29, 30].
Statistical analyses
Categorical variables were evaluated using the Chi-square
test and presented as frequencies and percentages.
Continuous variables were analyzed with one-way analysis
of variance (ANOVA) or the Kruskal-Wallis test. The
Kolmogorov-Smirnov test was used to analyze the normal-
ity of the distribution of parameters. Results are presented
as the mean ± standard deviation (SD) for normally distrib-
uted variables and the median (interquartile range [IQR])
for variables with skewed distribution. Participants were
classified into quartiles according to their serum klotho
level. We analyzed the serum klotho value across the CKD
stages by Kruskall-Wallis test and P value is the difference
between CKD stages. P-for trend of klotho level with ad-
vanced CKD stages was measured by Jonckheere-Terpstra
test (Jonckheere trend test). We analyzed LVMI and PWV
across the klotho quartiles by ANOVA and P value is the
difference between klotho quartiles. P-for trend of LMVI
and PWV value with higher klotho quartiles was measured
using ANOVA trend analyses using polynomial contrasts.
We employed a multivariable linear regression model ana-
lysis with adjustment (enter method) to investigate the as-
sociations of left ventricular hypertrophy and PWV with
serum klotho level. LVMI and PWV are continuous vari-
ables. LMVI and PWV (dependent variables) corresponding
to the independent variables fulfilled the assumptions for
linear regression model: normality, homoscedasticity, inde-
pendence, and linearity. For all linear regression models,
variables were selected based on the prior studies and
physiological reasoning [31–33]. Collinearity among
variables was tested. P-values < 0.05 were considered
statistically significant. The SPSS statistical software (SPSS
version 18.0, Chicago, IL, USA) was used for all descriptive
and outcome analyses.
Results
Demographic and baseline clinical characteristics of
participants
The clinical characteristics of the study patients at enroll-
ment are shown in Table 1. Among 2101 patients, the
mean age was 53.6 ± 12.2 years, and 61.1% were male. The
mean eGFR was 53.0 ± 30.7 mL/min/m2. Patients with
diabetes mellitus (DM) and hypertension (HTN) com-
prised 33.9% and 96.1% of the subjects, respectively. The
median serum klotho level was 536 (interquartile range
[IQR]:420–667) pg/mL. Serum klotho levels according to
CKD stages are shown in Fig. 1. Advanced CKD stages
were associated with lower serum klotho levels (P < 0.001,
P for linear trend< 0.001).
Comparison of baseline characteristics according to
serum klotho levels
We compared baseline characteristics classified by the
klotho quartiles (Table 1). Patients in the highest (4th)
quartile group were younger and had a lower body mass
index (BMI). eGFR and hemoglobin levels were higher in
the 4th quartile klotho group. Uric acid, C-reactive protein
(CRP), phosphorus, and intact parathyroid hormo-
ne(iPTH) were lower in the 4th quartile klotho group.
Serum klotho and cardiovascular parameters
Ascending quartiles of klotho were significantly associated
with decreased LMVI (P < 0.001, P for linear trend< 0.001;
Fig. 2). A total of 509 (24.8%) patients had LVH (281
[22.4%] in male, 228 [28.6%] in female). LV geometry was
not significantly different among the klotho quartile groups
(P = 0.084). Table 2 summarizes the results of the multivar-
iable linear regression analysis of the association between
klotho and LVMI. After adjustment for age, gender, DM,
HTN, BMI, systolic blood pressure, eGFR, hemoglobin,
phosphorus, corrected calcium, and FGF23, serum klotho
had a significant inverse association with LVMI (β - 0.04;
95% CI -0.004, − 0.00007; P = 0.041; Table 2). baPWV had
a tendency of decreasing across the quartiles of klotho but
it is not statistically significant (P = 0.127; Fig. 3A).Ascend-
ing quartiles of klotho were significantly associated with
decreased hfPWV (P = 0.022, P for linear trend = 0.002;
Fig. 3B). However, there was no significant association of
serum klotho with baPWV (β 0.003; 95% CI -0.04, 0.05;
P = 0.876) and hfPWV (β − 0.013; 95% CI -0.06, 0.034; P =
0.564) after adjustment (Table 3). AAC and CACS values
were not significantly different among the klotho groups
(Table 1). Systolic or diastolic heart function values as
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Table 1 The clinical characteristics of the study subjects at enrollment stratified by serum klotho level
Characteristics Total
(N = 2101)













Age (mean ± SD) 53.6 ± 12.2 54.0 ± 11.8 54.6 ± 11.9 53.5 ± 12.2 52.2 ± 12.5 0.015 0.007
Gender, male, n (%) 1284 (61.1) 330 (63.0) 319 (60.4) 317 (60.6) 318 (60.5) 0.795 0.440
BMI (kg/m2) 24.5 ± 3.4 24.8 ± 3.5 24.6 ± 3.2 24.5 ± 3.4 24.2 ± 3.3 0.036 0.005
DM, n (%) 712 (33.9) 171 (32.6) 192 (36.4) 172 (32.9) 177 (33.7) 0.560 0.962
HTN, n (%) 2020 (96.1) 507 (96.8) 517 (97.9) 501 (95.8) 495 (94.1) 0.011 0.007
SBP (mmHg) 128.5 ± 16.4 129.3 ± 16.1 128.5 ± 16.6 127.9 ± 16.9 128.5 ± 16.1 0.599 0.370
DBP (mmHg) 76.9 ± 11.2 76.7 ± 11.8 77.0 ± 11.1 76.6 ± 11.2 77.2 ± 10.5 0.786 0.667
ACEi or ARB, yes, n (%) 1795 (85.6) 458 (87.4) 461 (87.5) 442 (84.7) 434 (82.7) 0.075 0.013
eGFR
(ml/min/1.73m2)
53.0 ± 30.7 48.2 ± 28.6 47.6 ± 27.8 54.6 ± 31.6 61.7 ± 32.5 < 0.001 < 0.001
Hemoglobin (g/dL) 12.8 ± 2.0 12.6 ± 1.9 12.6 ± 2.0 12.9 ± 2.0 13.3 ± 2.1 0.001 < 0.001
Uric acid (mg/dL) 7.0 ± 1.9 7.4 ± 2.0 7.2 ± 1.9 6.9 ± 1.9 6.6 ± 1.8 < 0.001 < 0.001
Albumin (g/dL) 4.2 ± 0.4 4.1 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.5 0.316 0.068
Total cholesterol (mg/dL) 174.3 ± 39.4 174.0 ± 39.3 172.0 ± 38.0 172.5 ± 40.3 178.8 ± 39.6 0.021 0.053
CRP, median,
(Q1, Q3) (mg/dL)
0.06 (0.02, 0.17) 0.08 (0.03, 0.20) 0.06 (0.03, 0.16) 0.06 (0.02, 0.16) 0.05 (0.02, 0.13) < 0.001 < 0.001
Phosphorus (mg/dL) 3.7 ± 0.7 3.8 ± 0.7 3.7 ± 0.7 3.7 ± 0.7 3.6 ± 0.6 0.004 0.001
Corrected Ca (mg/dL) 9.0 ± 0.4 9.0 ± 0.4 9.0 ± 0.5 9.0 ± 0.4 8.9 ± 0.4 0.505 0.530
Klotho, median
(Q1, Q3) (pg/mL)
536 (420, 667) 335 (269, 383) 479 (449, 505) 593 (562, 626) 788 (714, 913) < 0.001 < 0.001
25(OH)VitD, median
(Q1, Q3) (ng/mL)
16.5 (12.7, 21.3) 16.7(13.5, 21.7) 16.6(13.1, 21.2) 16.4(12.6, 21.3) 16.1(12.1, 21.0) 0.040 0.005
1,25(OH)2VitD, median
(Q1, Q3) (pg/mL)
25.4 (20.1, 33.7) 26.4 (20.1, 36.2) 24.6 (19.1, 31.6) 24.3 (19.4, 32.5) 26.6 (21.4, 34.4) < 0.001 0.599
iPTH, median
(Q1, Q3) (pg/mL)




17.9 (0.4, 31.3) 18.5 (0.3, 30.2) 19.0 (1.0, 32.3) 18.6 (0.8, 31.5) 10.4 (0.2, 31.4) 0.094 0.419
UACR, > 300
mg/g, n (%)
884 (49.9) 217 (52.3) 255 (56.0) 205 (45.5) 207 (45.9) < 0.001 < 0.001
LVMI, median
(Q1, Q3) (g/m2.7)
40.3 (33.8, 48.6) 41.3 (34.7, 50.2) 40.9 (34.4, 49.2) 39.5 (33.5, 49.3) 39.6 (32.5, 46.7) < 0.001 < 0.001
LVH, n (%) 509 (24.8) 145 (28.3) 139 (27.0) 128 (24.8) 97 (19.2) 0.004 0.001
LV geometry, n (%) 0.084 0.006
Normal 1248 (60.9) 303 (59.1) 304 (59.0) 316 (61.2) 325 (64.2)
Concentric
remodeling
293 (14.3) 65 (12.7) 72 (14.0) 72 (14.0) 84 (16.6)
Eccentric LVH 254 (12.4) 76 (14.8) 70 (13.6) 60 (11.6) 48 (9.5)
Concentric LVH 255 (12.4) 69 (13.5) 69 (13.4) 68 (13.2) 49 (9.7)
baPWV (cm/s) 1534 ± 344 1552 ± 348 1552 ± 322 1527 ± 357 1507 ± 347 0.127 0.024
ahfPWV (cm/s) 1018 ± 274 1053 ± 300 1028 ± 257 1005 ± 277 989 ± 258 0.022 0.002
AAC ≥ 1, n (%) 703 (35.0) 172 (35.0) 194 (38.0) 183 (36.6) 154 (30.6) 0.079 0.127
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LVEF and E/E’ were not significantly different among the
klotho groups (Table 1).
Discussion
The kidney is the principal organ for production of klotho,
and CKD is known to be associated with a klotho-
deficiency state. CKD patients suffer from a high burden
of CVD. In the present study, the serum klotho level was
lower in advanced CKD stages. Klotho exhibited an inde-
pendent negative association with LVMI. However, there
was no significant association between klotho and PWV
after adjustment in our subjects. Abdominal aorta
calcification and coronary artery calcification were not
significantly different among the klotho quartile groups.
No differences in systolic or diastolic heart dysfunction
were observed across klotho quartiles.
Previous studies showed that CKD patients were more
likely to have cardiac structural changes in the absence
of decreased LV ejection fraction [34, 35]. Lower preva-
lence of systolic and diastolic heart dysfunction was not
surprising, given the exclusion of subjects with severe
heart failure (New York Heart Association Class III or
IV) from enrollment in the present study.
Xieet al. [12] showed that klotho-deficient CKD mice have
aggravated cardiac hypertrophy and cardiac fibrosis com-
pared with wild-type CKD mice. Intravenous delivery of a
transgene encoding soluble klotho attenuated cardiac hyper-
trophy in the klotho-deficient CKD mice. The authors ex-
plained that downregulation of the stress-induced transient
receptor potential canonical 6 (TRPC6)-mediated gene amp-
lification loop by soluble klotho may play a role in the cardio-
protection of uremic hearts [36].Yang et al.[16]reported that
klotho protects against indoxyl sulphate-induced cardiac
hypertrophy in CKD mice. They also showed that serum
Table 1 The clinical characteristics of the study subjects at enrollment stratified by serum klotho level (Continued)
Characteristics Total
(N = 2101)













CACS > 100, n (%) 498 (24.6) 133 (26.2) 131 (25.7) 121 (24.0) 113 (22.6) 0.528 0.143
LVEF < 50% 30 (1.5) 8 (1.5) 5 (1.0) 7 (1.3) 10 (2.0) 0.607 0.497
E/E’ > 15 176 (8.6) 46 (9.0) 47 (9.1) 42 (8.2) 41 (8.1) 0.923 0.536
a1243 patients measured hfPWV (vs. 1907 patients measured baPWV) at the study enrollment
SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate by CKD-EPI creatinine equation; CRP, C-reactive protein; Ca, calcium; 25(OH)VitD, 25-hydroxy vitamin D; 1,25(OH)2VitD,
1,25-hydroxy vitamin D; iPTH, intact parathyroid hormone; FGF23, fibroblast growth factor 23; UACR, random urine albumin-creatinine ratio; ACEi, angiotensin
converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; baPWV, brachial-to-ankle pulse
wave velocity; hfPWV, heart-to-femoral pulse wave velocity; AAC, Abdominal aorta calcification; CACS, coronary artery calcium score; LVEF, left ventricular ejection
fraction; E/E’, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E’)
Fig. 1 Serum klotho levels across CKD stages. Advanced CKD stages
were associated with lower serum klotho levels (P < 0.001, P for
linear trend < 0.001). NS, non significant
Fig. 2 Mean left ventricular mass index across the quartiles of
klotho. Ascending quartiles of klotho were significantly associated
with decreased left ventricular mass index (P < 0.001, P for linear
trend < 0.001). NS, non significant
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klotho levels are associated with the development of LVH in
patients with CKD. They did not show an association be-
tween klotho and LVMI for CKD patients in an adjustment
model. Most animal study results have suggested that klotho
deficiency is associated with cardiac hypertrophy. However,
clinical studies have shown mixed results with regards to
serum klotho and cardiac hypertrophy. Tanaka et al. [37] re-
ported that the lowest klotho tertile was associated with LV
hypertrophy and systolic dysfunction only among patients
with CKD stage G3a and G3b, respectively. Buiten et al. [17]
showed that serum klotho was not independently associated
with CVD, including LVMI, among 127 dialysis patients. This
study was conducted with a small number of dialysis patients
compared to our study. They also described that the associ-
ation of soluble klotho with cardiovascular parameters might
be diminished since the patients already developed end stage
renal disease [17]. Seiler et al. [38] showed that soluble klotho
was not significantly associated with cardiovascular outcomes
for 444 patients with CKD stage 2–4. They did not assess
each of cardiovascular parameters and mean eGFR was lower
than that of our study subjects (45 ± 16 vs. 53.0 ± 30.7 ml/
min/1.73m2). Our study included all stages of CKD patients
and presented that klotho could be a marker of LVMI in
predialysis CKD patients. The reason for the discrepancies
between those studies and ours remains uncertain. However,
there are possible explanations. First, these studies differed in
race, kidney function, and number of subjects. Second, we
examined cardiovascular parameters, rather than
cardiovascular outcomes. Thirdly, patients with severe heart
failure (New York Heart Association Class III or IV) were ex-
cluded in our study. However, the present study has a much
greater statistical power, due to a larger number of CKD sub-
jects analyzed. Soluble klotho plays important roles in anti-
aging, anti-oxidant, and anti-vascular calcification [39],and
CKD as a klotho-deficient state may have a close association
with chronic cardiovascular complications. The present study
showed the association of klotho with LVMI in a large num-
ber of CKD patients, with adjustment for markers of mineral
bone metabolism such as phosphorous and calcium.
In an experimental study, klotho gene delivery into
skeletal muscle inhibited medial hypertrophy of the aorta in
an animal model of atherosclerotic disease [40], and klotho
deficiency–induced arterial stiffening was mediated by up-
regulation of aldosterone levels [14]. Soluble klotho
protects endothelial integrity by regulating calcium entry
into vascular endothelial cells [40, 41]. Kitagawa et al. [42]
reported that the serum klotho level was a significant deter-
minant of arterial stiffness, defined as baPWV ≥1400 cm/s
in 114 CKD patients. They showed a significant association
only at baPWV ≥1400 cm/s. In our study, we also analyzed
hfPWV as a central arterial stiffness marker. In another
clinical study, arterial stiffness measured by baPWV in-
creased in 109 CKD patients, but it was not related to
klotho [43]. This study was performed only with a small
number of diabetic CKD patients. Thus, there have been
discrepancies among clinical study results. Further studies
Table 2 Multivariable linear regression analysis presenting associations between klotho and left ventricular mass index
Variable Model A Model B Model C
β (95% CI) P- value β (95% CI) P- value β (95% CI) P- value
Klotho (pg/mL) − 0.09 (− 0.006, − 0.002) < 0.001 −0.079 (− 0.005, − 0.002) < 0.001 −0.04 (− 0.004, − 0.00007) 0.041
Model A: Adjusted for klotho, age and gender
Model B: Adjusted for klotho, age, gender, DM, HTN, BMI, and SBP
Model C: Adjusted for klotho, age, gender, DM, HTN, BMI, SBP, eGFR, hemoblogin, phosphorus, corrected Ca, and FGF23
β, Standardized coefficient; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; BMI, body mass index; SBP, systolic blood pressure; eGFR, estimated
glomerular filtration rate by CKD-EPI creatinine equation; Ca, calcium; FGF23, fibroblast growth factor 23
Fig. 3 Mean pulse wave velocity across the quartiles of klotho. a Brachial-to-ankle pulse wave velocity had a tendency of decreasing across the
quartiles of klotho. b Ascending quartiles of klotho were significantly associated with decreased heart-to-femoral PWV (P = 0.022, P for linear trend
= 0.002). PWV, pulse wave velocity; NS, non significant
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are needed to elucidate the association between klotho and
arterial stiffness in CKD patients. This study has several
limitations. First, owing to the cross-sectional nature of the
study, it is hard to demonstrate the cause-effect inferences
about the relationship between serum klotho levels and car-
diac hypertrophy or arterial stiffness. Second, serum klotho
has a circadian variation, meaning that examination at a
fixed time is necessary [44]. Thirdly, we measured c-
terminal FGF23 in this study. Lack of agreement between
c-terminal and intact FGF23 measurements and also differ-
ences in their association with other biochemical parame-
ters have been reported [45]. However, both the higher c-
terminal and intact FGF23 values have been associated with
increased mortality and poor outcomes in CKD patients.
Conclusions
Serum klotho was an independent biomarker of LVMI but
not arterial stiffness and vascular calcification. Further
studies are warranted to elucidate the clinico-pathogenic
significance of klotho for cardiovascular parameters, and
whether any interventions to maintain or increase the
serum klotho level can prevent cardiovascular events and
mortality in CKD patients.
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